1 / 6

Case Study: Immtech, UNC and the Development of Drugs for Neglected Diseases

Case Study: Immtech, UNC and the Development of Drugs for Neglected Diseases. Anatomy of how a for-profit entity and a non-profit research program leveraged one another for mutual gain The stage:

jacqueline-chapman
Download Presentation

Case Study: Immtech, UNC and the Development of Drugs for Neglected Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case Study: Immtech, UNC and the Development of Drugs for Neglected Diseases • Anatomy of how a for-profit entity and a non-profit research program leveraged one another for mutual gain • The stage: • Immtech Pharmaceuticals – Publicly-traded company (AMEX: IMM) focused on anti-infective drug development • Tidwell and Boykin Labs – Labs at UNC and Georgia State focused on the discovery of novel anti-parasitic compounds

  2. The Research • GSU – UNC collaboration focuses on novel diamidines useful for treating infectious diseases. • GSU provides chemistry; UNC, pharmacology • Compounds useful for treating: • African Sleeping Sickness • -Parasitic infection spreading from lymph nodes to CNS • -Often fatal • Leishmaniasis • -Protozoal infection causing skin sores and organ damage • Malaria • -Number 1 killer in sub-Saharan Africa (>HIV)

  3. The Problem • Low/no commercial potential for large primary patient populations • Some commercial potential for small secondary patient populations (PCP, travelers to malaria-prone regions) • $60MM+ required to complete necessary clinical development • ….but risk/reward ratio not favorable for traditional commercial programs

  4. The Solution • Large contributions from philanthropic groups (>$40MM) toward development of anti-infectives for use in the Developing World • Clinical data generated applicable to clinical development for commercial programs • Philanthropic contributions leverage Immtech’s clinical development infrastructure • Immtech’s clinical development leverages data generated for philanthropic programs

  5. Logistics* • Immtech granted commercial rights to all indications • “Claw-back” rights for UNC/GSU to make compound available to treat Tryps/Leish in Developing World; as defined by GDP • Obligation for Immtech to provide API at fixed cost • Philanthropic funds administered by third party—discovery resources flow through UNC/GSU, clinical resources through Immtech • Partnership works because…. …each partner gains….and each partner is flexible *Details appearing in this presentation are publicly available through Immtech’s SEC filings

  6. The Postscript • Kidney toxicity emerges in late-stage clinical trials • Lead drug put on clinical hold IMPORTANT TO REMEMBER – RISK vs. REWARD

More Related